Eyenovia
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 57
- Market Cap
- $43.8M
- Website
- http://www.eyenovia.com
- Introduction
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Formosa Pharmaceuticals makes first shipment of APP13007 to US for commercialization
Formosa Pharmaceuticals shipped APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) to the U.S., with Eyenovia initiating pre-launch activities for a late September commercialization. APP13007, developed using Formosa’s APNT nanoparticle platform, offers a twice-daily dosing regimen for post-surgical inflammation and pain, compared to four times daily for other treatments.
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate ...
Formosa Pharmaceuticals announced the first shipment of its ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension 0.05% (APP13007), to the U.S., developed via APNT® nanotechnology. Partner Eyenovia, Inc. is preparing for commercialization in late September. The drug targets postoperative inflammation and pain, offering a more convenient dosing regimen.
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate)
Formosa Pharmaceuticals announced the first shipment of its ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), to the U.S., developed through its APNT® nanotechnology platform. Eyenovia, Inc. is expected to begin commercialization in late September. APP13007, the first FDA-approved ophthalmic use of clobetasol propionate, offers a more convenient dosing regimen for postoperative inflammation and pain.
Eyenovia Announces Taiwan Export License Approval to Begin Shipment to the ...
Monday, September 9, 2024
© Copyright 2024. All Rights Reserved by MedPath